Super-sized starch granules in engineered wheat better for T2DM, pharamaceuticals
NiveshIQ
NSE: GRANULES · Healthcare
Granules India Ltd.
₹841.85▼ ₹3.55 (-0.42%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GRANULES. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Granules India Ltd.
Granules India Limited is a leading player in the Indian healthcare sector, primarily engaged in the manufacture and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. The company offers a diverse portfolio of products across various therapeutic categories, including antiretroviral, anti-diabetic, anti-cancer, and anti-microbial. Granules India has a strong presence in the domestic market, with a significant share of the API market. The company has also been expanding its global footprint through strategic partnerships and acquisitions. In recent times, Granules India has received positive ratings and recommendations from various brokerage firms, including a 'Buy' rating with a target price of
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,507 Cr +92.40% | ₹4,482 Cr -0.60% | ₹5,366 Cr +19.70% |
| EBITDA Margin | 18.99% | 21.06% | 22.47% |
| Net Profit | ₹406.00 Cr +66.40% | ₹502.00 Cr +23.60% | ₹595.00 Cr +18.50% |
| EPS | ₹16.72 | ₹20.69 | ₹24.47 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Granules: FDA Raises No Concerns Over Gagillapur Facility, 7 Of 8 Sites Clean
Granules India के शेयर में तूफानी तेजी! Q1 में रेवेन्यू **22%** बढ़ा, मुनाफा **60%** उछला
🔒
+ 3 more stories about Granules India Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1,471 Cr, PAT ₹202 Cr, EPS ₹8.13, EBITDA margin 24.5%. Growth context: revenue YoY +14.8%, PAT YoY +17.3%, revenue QoQ +6.7%, PAT QoQ +34.5%. Street verdict: beat, revenue surprise +1.1%, PAT surprise +0.6%.
The absence of recent capex or expansion announcements suggests that the company will continue to rely on demand convers...
Management's commentary on the demand environment and margin trajectory will be a crucial input for the next analyst rev...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GRANULES
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GRANULES alongside your other holdings
Unlock full GRANULES research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Granules India Ltd.?
NiveshIQ detects active intelligence signals for Granules India Ltd. (GRANULES) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Granules India Ltd.?
Granules India Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,224,349.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.